
Melvin T Chin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7168035/publications.pdf Version: 2024-02-01



MELVIN T CHIN

#	Article	IF	CITATIONS
1	Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2010, 65, 597-605.	2.3	64
2	Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436). Clinical Cancer Research, 2014, 20, 4449-4458.	7.0	56
3	Primary pancreatic lymphoma – pancreatic tumours that are potentially curable without resection, a retrospective review of four cases. BMC Cancer, 2006, 6, 117.	2.6	49
4	Patient, general practitioner and oncologist views regarding long-term cancer shared care. Family Practice, 2018, 35, 323-329.	1.9	34
5	Using behaviour change and implementation science to address low referral rates in oncology. BMC Health Services Research, 2018, 18, 904.	2.2	22
6	Dexamethasone Modifies Cystatin C-Based Diagnosis of Acute Kidney Injury During Cisplatin-Based Chemotherapy. Kidney and Blood Pressure Research, 2017, 42, 62-75.	2.0	18
7	The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study. Oncologist, 2016, 21, 618-625.	3.7	12
8	Cutaneous metastasis of prostate carcinoma treated with radiotherapy: a case presentation. BMC Research Notes, 2014, 7, 505.	1.4	11
9	Achieving behaviour change for detection of Lynch syndrome using the Theoretical Domains Framework Implementation (TDFI) approach: a study protocol. BMC Health Services Research, 2016, 16, 89.	2.2	9
10	Codesigning consumer engagement strategies with ethnic minority consumers in Australian cancer services: the CanEngage Project protocol. BMJ Open, 2021, 11, e048389.	1.9	8
11	Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment. Melanoma Research, 2014, 24, 408-412.	1.2	7
12	Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: a case report. BMC Research Notes, 2016, 9, 386.	1.4	6
13	Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer. Oncology and Therapy, 2016, 4, 103-116.	2.6	5
14	Challenges and solutions to sharing a cancer follow-up e-care plan between a cancer service and general practice. Public Health Research and Practice, 2021, 31, .	1.5	5
15	What does co-design mean for Australia's diverse clinical workforce?. Australian Health Review, 2022, 46, 60-61.	1.1	4
16	Rationale for treatment durations of targeted cancer agents. Lancet Oncology, The, 2010, 11, 1113-1115.	10.7	3
17	Use of neostigmine in capecitabine-induced paralytic ileus. Tumori, 2013, 99, e225-e228.	1.1	1
18	The plot thickens: Archetypal narrative structure in the melanoma patient journey. Cogent Medicine, 2018, 5, 1484053.	0.7	1

Melvin T Chin

#	Article	IF	CITATIONS
19	Correlation between initial tumour volume and treatment duration on Dabrafenib: observation study of subjects with BRAF mutant melanoma on the BRF112680 trial. BMC Cancer, 2020, 20, 342.	2.6	1
20	Standard-Dose Osimertinib in EGFR-Mutated Non–Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease. JCO Precision Oncology, 2021, 5, 561-568.	3.0	1
21	Use of neostigmine in capecitabine-induced paralytic ileus. Tumori, 2013, 99, e225-8.	1.1	1
22	Durvalumab and multimodality therapy in a patient with multiple recurrent and unresectable cutaneous squamous cell carcinoma. Internal Medicine Journal, 2022, 52, 1103-1104.	0.8	0